Related Experiment Video
Updated: Jun 17, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications
Lifeng Gan1,2,3, Liying Zheng4, Junrong Zou2,3
1The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Abstract:
The three most common kinds of urologic malignancies are prostate, bladder, and kidney cancer, which typically cause substantial morbidity and mortality. Early detection and effective treatment are essential due to their high fatality rates. As a result, there is an urgent need for innovative research to improve the clinical management of patients with urologic cancers. A type of small noncoding RNAs of 22 nucleotides, microRNAs (miRNAs) are well-known for their important roles in a variety of developmental processes. Among these, microRNA-21 (miR-21) stands out as a commonly studied miRNA with implications in tumorigenesis and cancer development, particularly in urological tumors. Recent research has shed light on the dysregulation of miR-21 in urological tumors, offering insights into its potential as a prognostic, diagnostic, and therapeutic tool. This review delves into the pathogenesis of miR-21 in prostate, bladder, and renal cancers, its utility as a cancer biomarker, and the therapeutic possibilities of targeting miR-21.
Insights
MicroRNAs, specifically microRNA-21, show promise in diagnosing and treating common urologic cancers like prostate, bladder, and kidney cancer. Further research into miR-21 could improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Urologic cancers, including prostate, bladder, and kidney cancer, are leading causes of morbidity and mortality.
- Early detection and effective treatment are critical for improving patient survival rates.
- MicroRNAs (miRNAs) are small noncoding RNAs involved in cellular development and disease processes.
Purpose of the Study:
- To review the role of microRNA-21 (miR-21) in the pathogenesis of prostate, bladder, and renal cancers.
- To explore the potential of miR-21 as a biomarker for cancer diagnosis and prognosis.
- To discuss therapeutic strategies targeting miR-21 in urologic malignancies.
Main Methods:
- Literature review of studies investigating miR-21 in urologic cancers.
- Analysis of research on miR-21's involvement in tumorigenesis.
- Examination of data on miR-21's diagnostic and prognostic value.
Main Results:
- miR-21 is frequently dysregulated in prostate, bladder, and kidney cancers.
- miR-21 exhibits potential as a biomarker for early detection and predicting patient outcomes.
- Targeting miR-21 presents a promising therapeutic avenue for urologic cancers.
Conclusions:
- Dysregulation of miR-21 is implicated in the development of major urologic cancers.
- miR-21 holds significant potential as a diagnostic and prognostic biomarker.
- Targeting miR-21 offers a novel therapeutic strategy for urologic malignancies.
Related Concept Videos
01:22MicroRNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation